Fennec Pharmaceuticals Investor Relations Material

Fennec Pharmaceuticals Inc. is a specialized biopharmaceutical company primarily focused on developing treatments aimed at preventing ototoxicity (hearing loss) caused by platinum-based chemotherapy in pediatric cancer patients. Its flagship product, PEDMARK, represents a formulation of sodium thiosulfate designed to mitigate this side effect, catering to a niche yet critical aspect of pediatric oncology care. The company is headquartered in Research Triangle Park, North Carolina, and its shares are listed on the Nasdaq.